Rufinamide is an anticonvulsant medication used to treat seizures in patients with Lennox-Gastaut syndrome. However, the drug is not completely pure and may contain impurities, which can affect its efficacy and safety. These impurities can arise during the manufacturing, storage, or transportation of Rufinamide, and therefore, it is essential to monitor and control their levels. The most common impurities found in Rufinamide include related substances, residual solvents, heavy metals, and organic impurities. These impurities can be harmful to the body and cause adverse effects on the patient's health. Therefore, it is crucial to ensure that Rufinamide is free of impurities and meets the quality standards before it is prescribed to patients.
